Comparison of 10 and 20 µg/Kg/day PD-Grastim in Stem Cell Mobilization in Patients with Hematologic Malignancies Candidate for Autologous Stem Cell Transplantation

Seyed Reza Safaei, Ramazanali Sharifian, Amir Hossein Emami, Farhad Shahi, Niloufar Ghodrati, Saba Nemati Ahmadabad

Abstract


Introduction: Today, autologous peripheral blood stem cell transplantation is considered as a substitute procedure for Autologous bone marrow transplantation. Treatment with G-CSF mobilizes CD34+ HSCs from bone marrow into peripheral blood and could be used as a marker for hematopoietic stem cells mobilization and subsequent apheresis. Methods: In this study, 60 patients that had hematologic malignancies were randomly categorized into the two groups and were given PD-grastim (group A: 20 μg/kg/day and B: 10 μg/kg/day) to evaluate 10 and 20 μg/kg/day of PD-grastim in stem cell mobilization for autologous transplantation. Their CD34+ cell enumeration was carried out when leukocyte count was reached above 10000 cells/μl. Apheresis was also carried out when CD34+ count was reached above 16 cells/μl. Results: Results of the groups A and B were statistically analyzed and there was a meaningful statistical difference in gender, drug taking day numbers, apheresis numbers, hospitalization period and injected blood units. Based on the results, group A patients had lesser hospitalization period and apheresis number than group B. Conclusion: This indicates that utilization of PD-grastim at dose 20 μl/kg/day has better therapeutic effects on the patients with hematologic malignancies and could be considered as the major therapeutic regimen.

Keywords


Hematopoietic stem cells, Autologous transplantation, G-CSF, CD34+, Hematologic malignancy

Full Text:

PDF

References


Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG, Niederwieser DW. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biology of blood and marrow transplantation. 2008 Nov 30;14(11):1279-87.

Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003 Sep 15;102(6):2004-13.

Rowley SD, Loken M, Radich J, Kunkle LA, Mills BJ, Gooley T, Holmberg L, McSweeney P, Beach K, MacLeod B, Appelbaum F. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system. Bone marrow transplantation. 1998 Jun 15;21(12).

Jardin F. Development of autoimmunity in lymphoma. Expert review of clinical immunology. 2008 Mar 1;4(2):247-66.

Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends in biotechnology. 2006 Apr 30;24(4):150-4.

Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, Goldschmidt H, Ho AD. Poor mobilization of hematopoietic stem cells—definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation. 2010 Apr 30;16(4):490-9.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biology of Blood and Marrow Transplantation. 2008 Sep 30;14(9):1045-56.

Hogge DE, Lambie K, Sutherland HJ, Benny WB, Dalal B, Currie C, Barnett MJ, Eaves AC, Eaves CJ. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Bone marrow transplantation. 2000 Mar 1;25(6):589.

Jain KK. Cell Therapy of Cancer. InApplications of Biotechnology in Oncology 2014 (pp. 473-507). Springer New York.

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology. 2006 Jul 1;24(19):3187-205.

Sutherland DR, ANDERSON L, KEENEY M, NAYAR R, Chin-Yee IA. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. Journal of hematotherapy. 1996 Jun;5(3):213-26.

Bendall LJ, Bradstock KF. G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine & growth factor reviews. 2014 Aug 31;25(4):355-67.

Cooper Jr JA, White DA, Matthay RA. Drug-induced pulmonary disease: Part 1: Cytotoxic drugs 1, 2. American Review of Respiratory Disease. 1986 Feb;133(2):321-40.

Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, Devine S. Stem cell mobilization. ASH Education Program Book. 2003 Jan 1;2003(1):419-37.

Jantunen E, Varmavuo V, Valtola J. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Expert review of hematology. 2016 Aug 2;9(8):723-32.

Takeyama K, Ohto H. PBSC mobilization. Transfusion and apheresis science. 2004 Dec 31;31(3):233-43.

Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012 Jan;26(1):34.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biology of Blood and Marrow Transplantation. 2008 Sep 30;14(9):1045-56.

Smart N, Riley PR. The stem cell movement. Circulation research. 2008 May 23;102(10):1155-68.

Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. Journal of Experimental Medicine. 2002 May 6;195(9):1145-54.

Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008 May 1;22(5):941.

Poletto V. Circulating Endothelial Progenitor Cells from a patients with renal cell carcinoma display aberrant VEGF regulation, reduced apoptosis and altered ultrastructure.

To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011 Oct 27;118(17):4530-40.

Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF–induced progenitor cell mobilization as determined by CD26−/− mice. Experimental hematology. 2003 Nov 30;31(11):1126-34.

Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nature reviews. Molecular cell biology. 2014 Dec;15(12):786.

van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, van der Holt B, Lokhorst HM, Sonneveld P. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study. European Journal of Cancer. 2004 May 31;40(8):1159-69.

Shi Q, Cox LA, Hodara V, Wang XL, VandeBerg JL. Repertoire of endothelial progenitor cells mobilized by femoral artery ligation: a nonhuman primate study. Journal of cellular and molecular medicine. 2012 Sep 1;16(9):2060-73.

Kao GS, Kim HT, Daley H, Ritz J, Burger SR, Kelley L, Vierra‐Green C, Flesch S, Spellman S, Miller J, Confer D. Validation of short‐term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion. 2011 Jan 1;51(1):137-47.

Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, Yamada T, Uchimaru K, Tojo A, Shirafuji N, Kodo H. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004 Dec 1;104(12):3813-20.

Swerdlow SH, Habeshaw JA, Murray LJ, Dhaliwal HS, Lister TA, Stansfeld AG. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. The American journal of pathology. 1983 Nov;113(2):181.

Takeyama K, Ohto H. PBSC mobilization. Transfusion and apheresis science. 2004 Dec 31;31(3):233-43.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases. 2002 Mar 15:730-51.

Glück S. Abstracts: 2nd International Conference on High Dose Chemotherapy: Innovation and Evolution. Biology of Blood and Marrow Transplantation. 2002 Jun 30;8(6):336-47.

Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nature medicine. 2013 Nov 1;19(11):1450-64




DOI: http://dx.doi.org/10.7575/aiac.abcmed.v.6n.1p.18

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2019 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine